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bstract
ntroduction:  Functional bowel disorders (FBDs) significantly affect a person’s daily life; however, because their diagnosis is mostly based on
ymptom presentation, time to diagnosis is long. This delay in diagnosis remains true even when other methods, such as biochemical parameters,
mmunogenic and inflammatory markers, are used to differentiate the type of disorder. As treatment approaches are mainly symptom-based and
ften result in suboptimal outcomes, mind–body therapies may offer benefits either used alone or in combination with pharmacological treatments.
ethodology:  Thus, the purposes of this article are to: (1) describe the scientific knowledge based on currently available clinical trials of mind–body
herapies for FBDs, (2) examine potential benefits of using such therapies and, (3) provide recommendations regarding their clinical application
n the treatment of FBDs. The literature search covered the last decade from June 2002 to June 2012 and resulted in a total of 19 original research
rticles that met the inclusion criteria. The four common mind–body therapies, which include yoga, hypnotherapy, cognitive behavioral therapy,
nd biofeedback, were examined in this article.
onclusion:  The heterogeneity of clinical study designs as well as the wide disparity in defining primary outcome variables often limits the compar-son of studies on the same mind–body therapy. Overall findings of these studies were promising, but not conclusive, and further recommendations
or the research direction of mind–body therapies are proposed.
ublished by Elsevier GmbH.
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Functional bowel disorders (FBDs) represent a significant
ortion of gastrointestinal disorders with a high prevalence esti-
ated in the range of 15–35% of adults [1,2]. The classification
nd diagnosis of FBDs is based on symptom representation
nd has been classified by the Rome foundation into irritable
owel syndrome (IBS), functional bloating, functional constipa-
ion, functional diarrhea, and unclassified FBDs [1]. The most
Abbreviations: FBD, functional bowel disorder; IBS, irritable bowel syn-
rome; 5-HT, serotonin; CAM, complementary and alternative medicine; CBT,
ognitive behavioral therapy; GI, gastrointestinal.
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ttp://dx.doi.org/10.1016/j.eujim.2013.03.007ecent Rome III criteria define FBDs as a subgroup of func-
ional gastrointestinal disorders with onset of symptoms at least
 months prior to diagnosis and other diagnostic criteria active
or 3 months [3]. In spite of differential diagnosis and classifica-
ion, treatment for FBDs is primarily based on patient-specific
ymptoms because of their unclear pathophysiology as well as
ignificant overlap in symptoms among the different types.
While previous classifications were based on the presence
f symptoms, the new classification indicates that pathophysi-
logical parameters such as morphological, biochemical, and
mmunogenic changes can be evaluated for the diagnosis of
BDs [4]. For instance, there is significant indication that
erotonin transmission and receptors, which are located in
he intestinal tract and central nervous system, as well as
mmunogenic responses, inflammatory markers, and preexis-
ing conditions, contribute to the development of IBS [5–7].
n addition, the development of functional constipation and
iarrhea—hallmarks of IBS—may result from an imbalance of
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holinergic and serotonergic nerve transmission and receptor
ysfunction in the enteric system [8]. Although more research
s needed, new ways of identifying and classifying symptoms
ave led to more frequent and accurate diagnoses of IBS in the
S [9].
More frequent diagnoses, however, do not correlate to better
harmacological treatment approaches, which have demon-
trated limited success due to the pain sensitivity that often
ccompanies other symptoms. For example, laxatives and the
ff-label use of a serotonin 5-HT4 receptor agonist, tegaserod,
re predominantly used for constipation [10] while opioid ago-
ists such as loperamide and diphenoxylate and a serotonin
-HT3 antagonist (i.e., alosetron), may be used for managing
iarrhea [5]. The reduction of bloating and gas formation—other
requent symptoms of FBDs—can be achieved with surfactants
nd changes in lifestyle and diet restrictions [9]. Smooth muscle
elaxants, tricyclic antidepressants, and selective serotonin reup-
ake inhibitors can also be used for general symptom relief [5].
n sum, despite the many pharmacological approaches that are
vailable and because of the variety of often conflicting symp-
oms, there is no silver bullet to alleviate conditions associated
ith FBDs.
Because pathophysiological as well as psychosocial compo-
ents affect symptom severity of FBDs [1], one of the solutions
ay be the use of mind–body therapies, which are defined as
focusing on the interactions among the brain, mind, body, and
ehavior, with the intent to use the mind to affect physical func-
ioning and promote health” [11]. Under this definition, yoga, Tai
hi, meditation, hypnotherapy, deep-breathing exercises, pro-
ressive relaxation, and acupuncture, are mind–body therapies
s they serve to raise awareness of body sensations and engage in
elf-regulation of body processes in order to alleviate symptoms
12,13]. One study pointed out that women with FBDs have
ignificantly lower expectations of success and benefits from
sychological interventions such as cognitive behavioral therapy
r yoga than from taking oral medications although psychosocial
actors predominantly determined improvement [14].
Although historically these therapies have not been popular,
ecent years have shown an increase in interest and use: indeed,
he 2007 National Health Interview Survey results showed that
early 4 out of 10 US adults use some form of complementary
nd alternative medicine (CAM) with a rise in mind–body ther-
pies, specifically deep-breathing exercises (12.7%), meditation
9.4%), and yoga (6.1%) [15]. Despite the rise in general pop-
larity, CAM was only used by 1.2% of US adults for stomach
nd gastrointestinal disorders [15], indicating that there is an
pportunity for CAM to play an increased role in the treatment
f FBDs, particularly if patients are as receptive to using it as
ecent surveys have shown. When Harris and Roberts asked 256
atients with IBS about the acceptability of certain treatments,
hey found that tablets were most acceptable (84%) followed by
ife-style changes (82%), yoga (77%), stomach cream (68%),
omeopathy (65%), heat pad (64%) and hypnotherapy (64%)
16]. Another study revealed that 50% of IBS patients are turning
o CAM because of low satisfaction levels with conventional
reatment, and that hypnotherapy and cognitive behavior ther-
py (CBT) were the most clinically effective, CAM treatment
m
I
ef Integrative Medicine 5 (2013) 296–307 297
pproaches [17]. However, because these approaches have limi-
ations that mind body therapies lack (e.g. hypnotherapy depends
pon the “hypnotizability” of a patient, while CBT depends upon
vailability and patient preference) the latter represents a power-
ul treatment for patients with FBDs. Thus, the purposes of this
rticle are to: (1) describe the scientific knowledge based on cur-
ently available clinical trials of mind–body therapies for FBDs,
2) examine potential benefits of using such therapies, and (3)
rovide recommendations regarding their clinical application in
he treatment of FBDs.
ethodology
Complementary and alternative medicine (CAM) can be cat-
gorized into five areas according to the National Center for
omplementary and Alternative Medicine (NCCAM), National
nstitute of Health (NIH). These are (1) Alternative Medical Sys-
ems, (2) Biological Based Therapies, (3) Mind/Body Therapies,
4) Manipulative and Body Based Therapies, and (5) Energy
herapies. This article will review current research regarding
he most commonly used mind–body therapies for FBDs in the
S, which are yoga, hypnotherapy, cognitive behavioral therapy,
nd biofeedback [18]. Acupuncture and massage therapy were
xcluded because the former is categorized as an “alternative
edical system” and the latter within “manipulative and body
ased therapies”.
Inclusion criteria of the literature search were (1) English
anguage only, (2) articles published between June 2002 and
une 2012, (3) Medline, PsycINFO, EBSCO, Alt-Health Watch,
INAHL, and PubMed databases, and (4) the search terms
mind–body therapies”, “yoga”, “hypnotherapy”, “cognitive
ehavioral therapy”, or “biofeedback”, in combination with
functional bowel disorders”, “irritable bowel syndrome”, “con-
tipation”, “functional abdominal pain”, or “diarrhea”. This
esulted in retrieval of a total of 518 references. Of those, review
rticles, protocols, case reports, duplicated publications, and
tudies with less than 20 patients were excluded for review.
inally, 19 original research articles met the review criteria
Fig. 1). The 19 original research articles for review included
andomized and non-randomized as well as non-blinded and
ingle-blinded studies because the nature of mind–body inter-
entions often do not allow for blinding (Table 1).
esults
oga
Yoga is a mind–body therapy with roots in ancient Indian
hilosophy that combines physical postures (asanas), breathing
echniques (pranayama), and relaxation or meditation in order
o balance the mind and body [19]. It has shown benefits for a
ariety of acute and chronic disorders [20–23] and because of
his, is presently being used by 10% of IBS patients for symptomanagement [18].
Although clinical studies involving yoga and patients with
BS are few, there is some evidence to suggest a positive influ-
nce of yoga on both pain and anxiety. For example, one study
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Table 1
Clinical studies involving mind–body therapies for the treatment of functional bowel disorders.
Reference Publication year Country Sample characteristics
and size (N)
Study design # of sessions (duration) Outcome
Yoga
Taneja et al. [24] 2004 Canada IBS-D, IBS
determined by Rome
II criteria (N = 22)
Randomized,
non-double blinded,
non-placebo
controlled
8 sessions (2 months) Significant reductions in bowel
symptom, state anxiety, and autonomic
symptom scores comparable or greater
than standard therapy
Kuttner et al. [25] 2006 Netherlands All IBS forms, IBS
determined by Rome I
criteria (N = 28)
Randomized,
non-double blinded,
non-placebo
controlled
1 yoga session followed by 4 weeks of
home sessions, wait-list control received
same protocol after 1 month wait (2
months)
Significant reduction in GI symptoms
and emotion-focused pain coping in both
groups after yoga intervention,
non-significant reductions in pain
intensity and anxiety scores
Brands et al. [26] 2011 United States All IBS forms and
functional abdominal
pain determined by
Rome III criteria
(N = 20)
Non-randomized,
non-double blinded,
non-placebo
controlled
10 yoga sessions over 12 weeks in two
groups of children (ages 8–11 and
12–18) with 3 month follow-up period
Results of the pilot study indicate
significant decreases in pain intensity
scores for children in both age groups
compared to baseline
Hypnotherapy
Gonsalkorale et al. [33] 2004 United States All IBS forms, IBS
determined by Rome I
criteria (N = 78)
Non-randomized,
non-double blinded,
non-placebo
controlled
12 sessions (12 weeks) Significant improvements in HAD scores
and IBS symptoms compared to baseline
Palsson et al. [34] 2002 United Kingdom All IBS forms, IBS
determined by Rome I
criteria (N = 42)
Randomized,
non-double-blinded,
non-placebo-
controlled
7 sessions with post-evaluation (7– 28
weeks)
Significant reduction in IBS symptoms in
both pain-specific and non-pain-specific
hypnotherapy groups, reductions in
anxiety and depression scores for
pain-specific hypnotherapy
Vlieger et al. [36,44] 2007 United Kingdom Pediatric patients with
functional abdominal
pain or IBS, IBS
determined by Rome
II criteria (N = 53)
Randomized,
non-double-blinded,
non-placebo
controlled
6 sessions over 3 months with follow-up
(12 weeks with 1 year follow-up)
Significant improvement in IBS
symptom scores, abdominal pain and
distension, and anxiety compared to
standard medical therapy, at 5 year
follow-up pain intensity and frequency
scores remained significantly lower in
both the supportive therapy and
hypnotherapy groups
Lea et al. [37] 2003 United Kingdom All IBS forms, IBS
determined by Rome I
criteria (N = 40)
Non-randomized,
non-double-blinded,
non-placebo
controlled
12 sessions over 3 months with follow-up
(12 weeks with 2 week follow-up)
Moderate improvement in rectal
sensitivity, significant improvement in
anxiety and depression symptoms
compared to baseline
Gonsalkorale et al. [42] 2003 United Kingdom All IBS forms, no
documentation of IBS
diagnosis (N = 204)
Non-randomized,
non-double-blinded,
non-placebo
controlled
12 sessions over 3 months (12 weeks
with 6 year follow-up)
Significant improvement in IBS
symptom scores, abdominal pain and
distension, and HAD compared to
pre-treatment in responders
Roberts et al. [43] 2006 United Kingdom All IBS forms, no
documentation of IBS
diagnosis (N = 81)
Randomized,
non-double-blinded,
placebo-controlled
5 sessions over 5 weeks with 12 month
follow-up
Significant improvement in overall
symptom scores, pain, and diarrhea
scores compared to placebo after 3
months, but results were not maintained
after 12 months with no difference
between groups
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Table 1 (Continued)
Reference Publication year Country Sample characteristics
and size (N)
Study design # of sessions (duration) Outcome
Lindfors et al. [47] 2012 Sweden All IBS forms, IBS
determined by Rome
II criteria in two
separate studies
(N = 90 for study 1,
N = 48 for study 2)
Randomized,
non-double-blinded,
placebo-controlled
12 session over 3 months of
hypnotherapy in private practices or
individual therapy for the control group
(study 1) or in a hospital (study 2) with a
wait-list as control group
Significant and maintained
improvements in overall symptom scores
in study 1 patients compared with
placebo group, smaller and
non-maintained improvements in
symptom scores for patients in study 2
compared to baseline and control group
Flik et al. [49] 2011 Netherlands All IBS forms, IBS
determined by Rome
III criteria (N = 354)
Randomized,
non-double-blinded,
placebo-controlled
6 sessions over 12 weeks of individual
hypnotherapy, group hypnotherapy, or
educational supportive therapy (placebo)
Study results expected by end of 2013.
Cognitive behavioral therapy (CBT)
Tkachuk et al. [61] 2003 Canada All IBS forms, IBS
determined by Rome I
criteria (N = 28)
Randomized,
non-double-blinded,
non-placebo-
controlled
10 CBT sessions or symptom monitoring
with telephone contact over 9 weeks with
3 month follow-up
Significant improvements in cognitive
scale for functional bowel disorders,
assertiveness questionnaire, and short
form 36 health survey – physical health
component scale
Drossman et al. [55],
Weinland et al. [56]
2003, 2010 United States FBDs (IBS, functional
abdominal pain,
painful constipation,
and unspecified FBD),
no documentation of
FBD diagnosis
(N = 431)
Randomized,
non-double-blinded,
placebo-controlled
12 CBT, anti-depressant, or educational
sessions over 3 months (12 weeks with 1
year follow-up)
Significant improvements in satisfaction,
global well-being, and responder rate of
CBT group vs. education group at 1 year
follow-up, CBT as effective as
antidepressant in reducing IBS
symptoms
Kennedy et al. [58] 2006 United Kingdom All IBS forms, no
documentation of IBS
diagnosis (N = 149)
Randomized,
non-double-blinded,
non-placebo-
controlled
6 CBT sessions over 6 weeks in addition
to mebeverine hydrochloride for
treatment of IBS symptoms in
intervention group, only mebeverine
treatment in control group with 12 month
follow-up
Significant reduction in symptom scores
and increase in quality of life measures
in patients receiving CBT compared to
mebeverine alone although effects of
CBT were not lasting beyond 6 months
during follow-up
Mahvi-Shirazi et al. [60] 2008 Iran All IBS forms, IBS
determined by Rome
II criteria (N = 50)
Randomized,
non-double-blinded,
non-placebo-
controlled
8 CBT sessions over 2 months Significant improvements in IBS
symptoms (Rome-II questionnaire) and
psychological symptoms (SCL-90-R)
Jones et al. [57] 2011 Australia All IBS forms, IBS
determined by Rome I
criteria (N = 105)
Randomized,
non-double-blinded,
non-placebo-
controlled
8 CBT or relaxation sessions over 2
months (8 weeks with 1 year follow-up)
Significant improvements in mood
(HAD scale) and IBS symptoms (BSSS)
after CBT comparable to relaxation
therapy and standard medical care
Biofeedback
Ding et al. 2011 China Functional
constipation
determined by Rome
III criteria (N = 21)
Non-randomized,
non-double-blinded,
non-placebo-
controlled
10 1-h biofeedback sessions, initially
every other day followed by 2–3 times
per week for 8 weeks, manometry and
anal electrode were used to measure
sphincter contractions, patients were
asked to keep sphincter constrictions
within certain range through relaxation
and constriction of the pelvic floor
muscles
Significant improvements in several
psychological questionnaires (self-rating
anxiety scale, self-rating depression
scale), several variables on the 36-item
short-form health survey for quality of
life, and the Bristol stool scale. No
changes in autonomic function as
evaluated by high and low frequency
heart rate bands.
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tFig. 1. Flow chart illustrating th
valuated the effect of mixed Surya Nadi pranayama yoga
ostures and select breathing techniques in 22 patients with
iarrhea-predominant IBS and found that yoga was at least as
ffective as loperamide in reducing both anxiety and motil-
ty scores in IBS patients [24]. The subjects were split into
wo groups: one group received the standard pharmacological
nti-diarrhea treatment with loperamide while another group
racticed yoga twice a day for two months. Evaluation of anx-
ety and motility scores before, 1 month, and 2 months into
he intervention showed that yoga was at least as effective as
operamide in reducing both anxiety and motility scores in IBS
atients (p  < 0.01 for bowel symptom scores in conventional and
 < 0.001 in yoga group after 2 months compared to baseline;
 < 0.02 for state anxiety scores in conventional and p  < 0.004 in
oga group after 2 months compared to baseline). Furthermore,
ogic intervention resulted in significantly better improvement
n autonomic symptom score (p  < 0.05 for yoga group compared
o conventional group after 2 months of intervention), which is
n indicator of reduced parasympathetic tone while normalizing
he sympathetic activity to provide balance in motility. Another
tudy evaluated the effect of yoga on 25 IBS patients who were
iagnosed by Rome I criteria and aged 11–18 [25]. After an ini-
ial screening, they were given an instructional and introduced to
oga self-practice at home. Once they had engaged in practice
or one month, they were interviewed again using a 10-point
cale pain score, pain coping questionnaire, and the Children’s
epression inventory form. The authors found that there was
 significant difference in functional disability, child manifest
nxiety, and emotion-focused avoidance between the yoga and
aitlist group at a significance level of p < 0.1. In addition, gas-
rointestinal symptoms and anxiety-related avoidance behavior
ere significantly reduced after 1 month, further supporting the
dea that yoga can benefit patients with IBS [25]. However,
ue to the small sample size and the use of only descriptive
o
e
w
hction criteria for clinical trials.
tatistics, the study results remain questionable, especially in
ight of the higher p-value of 0.1 instead of the widely accepted
 < 0.05 with a potential for a type II error.
A similar pilot study evaluated yoga in two adolescent groups,
ged 8–11 and 12–18 years, who were diagnosed with either IBS
r functional abdominal pain according to Rome III criteria in
he Netherlands [26]. After 10 Hatha yoga sessions lasting 1.5 h
ith suggestive and general relaxation elements, the pain inten-
ity and frequency scores for both patient groups significantly
ecreased compared to baseline (p  = 0.031 and p  = 0.004 for
ain frequency in 8–11 and 12–18 year old group respectively,
 = 0.015 for pain intensity in 8–11 year old group). In particular,
he pain frequency score in the younger patient group remained
ignificantly lowered at a 3 month follow-up (p  = 0.04). Because
f the significant results, the authors plan to conduct a similarly
esigned study with a larger patient population to provide further
vidence for the benefits of yoga in treating FBDs.
Although there are only a few studies that indicate a benefit of
oga in the treatment of FBDs, the evidence to date suggests that
oga may alleviate pain and anxiety in a diverse patient popula-
ion. However, the current trials are limited by their small sample
ize, which indicates that further studies with larger sample sizes
re necessary to support the findings.
ypnotherapy
Hypnosis or hypnotherapy, is one of the oldest practices for
nduction and maintenance of a sedative or anesthetic state, and
s associated with relaxation, elevated mood, reduced pain sensi-
ivity as well as a lower heart and respiration rate [27]. Similar to
ther mind–body therapies, hypnosis induces a state of height-
ned internal awareness of and control over bodily processes
ithout losing control or consciousness [28]. The effects of
ypnosis are evident in certain brain regions, particularly the
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rontolimbic attention system, which is associated with being
ble to shift focus from unpleasant stimuli to pleasurable or
eutral emotions [29].
Because hypnosis has primarily been used to initiate a seda-
ive and anesthetic state, it has demonstrated effectiveness in
educing both acute pain during surgery as well as chronic pain
30–32]. Furthermore, hypnosis has been shown to help improve
BD symptoms as effectively as pharmacological treatments
27,33–38].
The application of hypnosis specifically for the treatment
f IBS has been introduced and utilized as gut-directed hyp-
otherapy by Peter Whorwell and colleagues at the University
ospital of South Manchester in the 1980s [39]. This approach
ocuses specifically on a framework that provides patients with
he necessary hypnotic skills to control gut function and reduce
ymptoms.
In fact, in one study, gut-focused hypnotherapy relieved pain
nd increased quality of life after 12 hypnotherapy sessions in 78
BS patients who did not respond to conventional pharmacolog-
cal treatments [33]. The overall extracolonic symptom score
ecreased by 70.7 points (p  < 0.01), the overall IBS symptom
core decreased by 159.7 points (p  < 0.001), and the over-
ll quality of life score increased by 75.4 points (p  < 0.001)
etween pre- and post-hypnotherapy intervention. Nearly all
arameters of the cognitive scale improved with the excep-
ion of the self-nurturance and perfectionism scores. Another
tudy found similar results for 42 IBS patients who were
reated with 12 weeks of hypnotherapy, in which significant
mprovements in rectal pain, sensitivity, anxiety, depression, and
omatic symptoms were observed [34,37]. This study consisted
f two sub-studies that used different evaluation techniques
o test the different hypotheses. In the first sub-study, which
onsisted of 18 patients, seven 45-min individual hypnosis ses-
ions were administered to two groups of 9 participants: one
roup received pain-specific verbal suggestions while the other
roup did not. Rectal muscle tone and pain threshold were
valuated in conjunction with a daily diary of GI symptoms,
ain frequency and severity, and administration of the Beck
epression inventory. The second sub-study consisted of 24
atients that were randomized into an immediate and delayed
ypnosis treatment groups. The immediate group received seven
ypnosis sessions with pain-specific verbal suggestions over
he course of 12 weeks after a 2 week baseline observa-
ion period while the delayed waiting-list group received the
ame hypnotherapy treatment after 4 months. Both groups
ere interviewed 4 months and 8 months after enrollment. All
atients in the first sub-study were evaluated with the phys-
cal symptoms inventory and an autonomic functioning test,
hich involved measurement of skin conductance, skin tem-
erature, and muscle tension via electromyography (EMG). The
esults showed an immediate effect on abdominal pain (p  < 0.001
etween baseline and posttreatment), bloating (p  = 0.002), and
tool consistency (p  = 0.003) with pain-specific and non-pain-
pecific hypnotherapy; however, there was no change in bowel
ovements per day (p  = 0.733). Significant improvements in
omatization (p  = 0.0001 pre-treatment vs. post-treatment), anx-
ety (p  = 0.008), and depression (p  = 0.03) were observed in the
o
s
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econd study. The effect of hypnotherapy lasted for at least
0 months after study admission with significant (p < 0.05)
mprovements in abdominal pain, bloating, and stool consis-
ency. These findings indicate that hypnosis is a promising
ind–body therapy for patients of FBDs.
Similarly, a review by Gholamrezaei and colleagues of 13
ypnotherapy, clinical studies showed that hypnotherapy was a
romising way to alleviate symptoms of IBS, but methodologic
nadequacies hampered its efficacy [40]. The authors provided
 list of recommendations that might improve the quality of
linical trials which included—among other suggestions—a
ell-defined study population, a large sample size to allow for
mall effect sizes, and the use of validated instruments to mea-
ure changes in a reliable manner.
Another review of hypnosis by Whorwell, which related the
pecific type of hypnotherapy to the outcome [41], found that
ut-directed or symptom-directed hypnotherapy can alleviate
olonic and non-colonic ailments related to IBS and improve
atient quality of life. Whorwell concluded that hypnotherapy
an influence psychological and gastrointestinal responses by
ltering the central processing of noxious stimuli and can thus
e used in the treatment of many disorders.
However, because these studies were limited by small sam-
le sizes, it is important to examine studies with larger sample
izes to establish validity. In a clinical study that included 204
BS patients, the long-term effects of hypnotherapy after a 12
eek hypnotherapy intervention were evaluated over the course
f 6 years [42] and revealed significantly improved pain severity
nd frequency, bloating, and overall quality of life, especially in
atients who continued to practice self-administered hypnother-
py. In addition, a 2007 Cochrane database review regarding
he use of hypnotherapy for IBS, which included a total of 147
atients in four studies between 1998 and 2006, demonstrated
hat, in comparison to conventional pharmacological therapy
lone, 5–12 hypnotherapy sessions significantly reduced the
verall symptom and abdominal pain scores after 3 months
38]. Although the authors of the review [38] found significant
hanges in frequency of bowel movements, abdominal pain, and
tool consistency, they were not able to determine an overall
onfidence interval for the improvements due to heterogene-
ty of the study outcome measures and evaluation tools. These
ndings are supported by a study of 81 IBS patients that were
andomized to receive 5 gut-directed hypnotherapy sessions over
he course of 5 weeks in addition to standard care or standard
are alone; results indicated significantly lower symptom scores
or pain (p  = 0.02), diarrhea (p  = 0.046), and overall quality of
ife (p  = 0.008) after 3 months [43]. The study notes though,
hat these differences could not be maintained in comparison
o the control group after 12 months, thus indicating a limit to
he chronic effects of hypnotherapy after intervention. These
ndings suggest that the results seen in smaller studies can be
eplicated on a larger scale, further establishing that hypnosis can
e an effective complementary treatment for chronic sufferers
f FBDs.
Because children with IBS may suffer from higher social
tigma, they could require special consideration in regards
o symptom alleviation. One study investigated the use of
3 rnal o
g
d
I
r
m
r
p
6
t
2
7
a
o
i
f
f
d
r
a
n
s
f
m
i
c
e
u
s
d
3
a
a
l
s
d
a
t
a
i
A
a
h
I
I
t
h
m
1
w
I
h
(
t
o
a
a
t
T
a
h
r
t
e
1
p
t
t
s
b
(
s
a
n
t
d
i
(
n
i
i
f
a
t
e
t
a
b
c
p
l
l
c
c
b
c
r
l
o
w
f
i
i
N
p
t02 O. Grundmann, S.L. Yoon / European Jou
ut-directed hypnotherapy in 53 children ages 8–18 who were
iagnosed with either functional abdominal pain (N  = 31) or
BS (N  = 22) according to Rome II criteria [36]. Patients were
andomized to receive either 6 hypnotherapy sessions over 3
onths or conventional treatment with supportive therapy. (The
esults were not separated into an IBS and functional abdominal
ain group, which is a limitation of the study.) However, at 3,
, and 12 months following the intervention, more children in
he hypnotherapy group showed either an improvement (26%,
2%, and 11%, respectively) or were in clinical remission (59%,
1%, and 85%, respectively) compared to the supportive ther-
py group. Both groups also showed a significant improvement
f pain intensity and frequency scores after 1 year follow-
ng the intervention (p  < 0.001 for hypnotherapy and p  = 0.002
or supportive therapy group). The authors conducted a 5-year
ollow-up study with the original group of patients [36] to
etermine pain intensity and frequency [44]. Both parameters
emained significantly lower after 5 years in the hypnotherapy
nd the supportive therapy arm of the initial study, but the hyp-
otherapy group presented significantly lower scores than the
upportive therapy group for both pain intensity (p  = 0.003) and
requency (p  = 0.002). Thus, although the primary study had
ostly positive outcomes, it provided few insights into specific
mprovements and was also limited by the inclusion of multiple
onditions in a small sample size.
The role of gut-directed hypnotherapy for IBS has also been
valuated in a patient population of 75 IBS patients diagnosed
sing Rome II criteria with evaluation of quality of life and IBS
ymptom questionnaires pre- and post-intervention [45]. Gut-
irected hypnotherapy was administered over the course of a
 month period in 5–7 sessions. The predominant symptoms of
bdominal pain and distension decreased significantly (p  < 0.05)
fter hypnotherapy as did almost all health-related quality of
ife measures (emotional (p  < 0.05), mental health (p  < 0.05),
leep (p  < 0.05), energy (p  < 0.05), physical health (p  < 0.05),
iet (p  < 0.001), social (p  < 0.05) and physical role (p  < 0.001)
s well as anxiety scores (p  < 0.05)). However, the limitation of
he study was the absence of a control group and the fact that
t least some of the improvements may have been linked to the
ndividual attention patients received from the nurse therapist.
s a result, the author advocates for an appropriately trained
nd educated GI nurse specialist to be involved in gut-directed
ypnotherapy for IBS patients.
Although gut-directed hypnotherapy is beneficial for many
BS patients, it appears to be of particular benefit to refractory
BS patients if they respond to the treatment. In a retrospec-
ive study, Lindfors et al. evaluated 208 patients who received
ypnotherapy between 2000 and 2006 using a subjective assess-
ent questionnaire for IBS symptoms [46]. Of the 208 patients,
03 were classified as responders that improved significantly
ith hypnotherapy with 73% still using hypnotherapy for their
BS symptoms during the 5-year follow-up. Overall, 100% of
ypnotherapy responders compared to 74% of non-responders
p < 0.001) considered gut-directed hypnotherapy a worthwhile
reatment. The use of hypnotherapy may serve both the purpose
f complementing the traditional pharmacological approaches
s well as providing patients who do not get adequate relief or
p
T
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re refractory to current conventional treatment an alternative
reatment for long-term relief of IBS symptoms and severity.
he relief experienced with the continued use of hypnother-
py appears to be sustained over years following the initial
ypnotherapy intervention.
Because IBS symptoms can alter with the environment,
esearchers evaluated the influence of setting on hypnotherapeu-
ic effectiveness. In this study, hypnotherapy sessions occurred
ither in the private practice of a clinical psychologist (study
) or a hospital setting (study 2) [47]. For both studies, 138
atients with refractory IBS were either randomly assigned
o receive hypnotherapy sessions over 12 weeks or assigned
o a waiting list in study 2 and receive supportive therapy in
tudy 1 as control treatments. At a follow-up of 3 months,
oth hypnotherapy groups showed significant improvements
p < 0.05) in symptom scores for IBS (total GI symptoms, sen-
ory symptoms, and bowel habits) compared to the baseline
nd respective control groups, but after 1 year, only the hyp-
otherapy group assigned to private practice sessions was able
o maintain reduced pain (p  < 0.01), bloating (p < 0.01), and
iarrhea (p  < 0.05), improved quality of life (emotional function-
ng (p  < 0.01), mental health (p  < 0.05), sleep (p  < 0.05), energy
p < 0.01), and social role (p  < 0.05)). The other 3 groups showed
o significant improvement compared to baseline, which may
ndicate that the hypnotherapy environment can significantly
nfluence clinical outcomes.
Similarly, because symptoms of IBS appear to be linked to
ood ingestion, researchers investigated the effect of hypnother-
py in post-prandial IBS patients refractory to conventional
herapy [48]. A total of 28 patients were assigned to receive
ither 1-h hypnotherapy sessions over 12 weeks or supportive
herapy for the same time period. Colonic distension was evalu-
ted at baseline and after 3 months using a barostat measurement
efore and after a 1-h duodenal lipid infusion. The results indi-
ated that hypnotherapy reduced symptoms, with higher balloon
ressure compared to supportive therapy, which significantly
owered gas (p  < 0.01), discomfort (p  < 0.01), and pain (p  < 0.01)
evels 1 h after lipid infusion. Due to these findings, the authors
oncluded that hypnotherapy affects both motor and sensory
omponents in the GI tract. This study, however, was limited
y a small sample size as well as a failure to include chole-
ystokinin measurements that impact significantly gastrocolonic
esponse. In addition, although this study was well-designed, it
acks questionnaires that are commonly used when evaluating
verall improvement and personal perception of the patients,
hich would further support the physiological findings. There-
ore, the study cannot be directly compared to other studies that
ncorporate these tools.
Based on the small sample size of previous studies involv-
ng IBS patients and hypnotherapy, a research group in the
etherlands is currently conducting a study including 354
atients with IBS diagnosis [49]. Patients are randomly assigned
o either individual or group hypnotherapy sessions and com-
ared to educational sessions that served as the placebo group.
he aim of the study is to provide further support for the
herapeutic application of hypnotherapy in reducing IBS symp-
oms as well as become one of the few studies that compares
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ndividual to group settings in a hypnotherapy intervention;
esults of the study are expected to be published at the end of
013.
Overall, hypnotherapy in the treatment of FBDs has shown
o be effective in a number of small clinical studies compared
o either wait-list or conventional pharmacological treatment
roups. It appears to be important to maintain regular hypnother-
py as an intervention to retain the effectiveness in reducing the
ymptoms of FBDs. However, inadequate study designs and het-
rogeneity in regards to the outcome measures warrant further
esearch in order to solidify the current findings. In addition, fre-
uency and durations of hypnotherapy interventions should be
nvestigated further for generalizability and maximum benefits
ith minimum frequency.
ognitive  behavioral  therapy
Patients with chronic conditions often have a negative atti-
ude that limits their ability to heal. However, this attitude can
e altered with cognitive behavioral therapy (CBT), which chal-
enges negative thoughts and causes patients to focus on a more
ositive outlook. A review of meta-analyses has shown CBT
o be effective in a number of chronic conditions [50] such
s depressive disorders [51], obesity [52], insomnia [53], and
hronic pain [54], but improvement with these conditions is not
mmediate; indeed, CBT requires at least 8–10 weekly sessions
efore improvement of symptoms is observed because it takes
ime for patients to adjust their perspective.
In addition to these chronic conditions, present research
urrently demonstrates the effectiveness of CBT in easing symp-
oms of FBDs. For example, in one large study that examined
31 female patients suffering from FBDs, CBT was at least
s effective as the antidepressant, desipramine in reducing
ymptoms [55]. Participants who were diagnosed with IBS,
ainful functional constipation, chronic functional abdominal
ain, or unspecified FBD according to Rome I criteria were
llocated to one of four treatment arms: 135 patients received
2 CBT sessions over the course of 3 months, 66 patients
eceived 12 modified-attentional control sessions during the
ame time period, 135 patients were randomized to receive
esipramine (final dose 150 mg/day), and 66 patients received
lacebo for 3 months. The composite score when comparing
BT with modified-attentional control and desipramine with
lacebo resulted in a significant improvement for CBT over
ontrol (p  < 0.0001) while desipramine was not significantly
etter than placebo (p  = 0.16). However, patient satisfaction
as significantly higher for the desipramine (p  = 0.011) and
BT (p  = 0.0004) groups. In addition, the CBT group presented
ith significantly (p  = 0.04) improved global well-being after 3
onths compared to the control. The responder rate was also
ignificantly higher in the CBT group vs. control (p  < 0.0001)
hile desipramine responder rate was not significantly differ-
nt from placebo. Interestingly, neither CBT nor desipramine
ad a significant effect on IBS quality of life and the McGill
verage daily pain scores. A further analysis of the outcome
uggests that satisfaction with treatment depends on cognitive
actors such as confidence in treatment, perceived control over
s
c
I
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he illness, and reduction in negative cognition of the symptoms,
hich may be better obtained with CBT than medication ther-
py alone [56]. In another, clinical study, 105 IBS patients were
iagnosed using Rome I criteria, and used either CBT (N  = 34),
elaxation therapy (N  = 36), or standard medical care (N  = 35)
57]. Results showed that CBT was able to affect mood (mainly
nxiety and depression) and change bowel symptoms as much
s relaxation and standard clinical care. However, this study was
imited because the CBT group received both standard clinical
are and relaxation therapy; thus, researchers were unable to
istinguish which variable determined the outcome. Although
hese findings are supportive of the use of CBT to ease FBD
ymptoms, more research is needed that investigates the poten-
ial mediator role that CBT plays between mood changes and
BS symptoms.
Another study investigated the complementary use of CBT
n patients with IBS receiving mebeverine hydrochloride as an
ntispasmodic treatment [58]. Only patients that were not well
ontrolled after 4 weeks of mebeverine treatment were random-
zed to receive either complementary CBT (N  = 72) or continue
ith only mebeverine (N  = 77). Patients receiving CBT in addi-
ion to mebeverine showed significant improvements in overall
ymptom severity scores (95% CI −109 to −32) and increased
uality of life (95% CI −35.4 to −7.9) at 3 months after the
ntervention. However, the benefits of CBT appeared to wane
ver time and did not reduce the overall social costs, following
 one-year follow-up period. This may point to the necessity of
 long-term supportive treatment with CBT in addition to com-
only used medication for IBS. The secondary analysis [58] of
he original study [57] indicated that behavioral and cognitive
omponents were important in the treatment of IBS and that
BS-related cognition and behaviors were actually mediators of
hange for IBS patients who received CBT [59].
When CBT as a complementary therapy is compared to
edication treatment alone, it is evident that CBT not only
mproves IBS-related symptoms, but also mental health and
ell-being. For example, in one study, 50 IBS patients who
ere diagnosed according to Rome II criteria were assigned
o receive medication treatment alone or 8 CBT sessions
ver the course of 2 months as a complementary therapy
60]. Results indicated significant reduction of all param-
ters in the CBT group following the intervention. These
arameters included Rome-II score (p  = 0.001), somatization
p = 0.0001), obsessive-compulsiveness (p = 0.0001), interper-
onal sensitivity (p  = 0.0001), depression (p  = 0.002), anxiety
p = 0.0001), hostility (p  = 0.0001), phobic anxiety (p  = 0.0001),
aranoid ideation (p  = 0.003), psychoticism (p  = 0.001), and gen-
ral symptom index (p  = 0.0001) that were evaluated using
tandardized questionnaires. Although the results were posi-
ive, this study was limited because it lacked a placebo for the
edication group alone.
Researchers primarily investigate CBT using individual ses-
ions, but recent studies have examined CBT in a group therapy
etting. A study conducted in Canada investigated the use of
ognitive behavioral group therapy in 28 patients diagnosed with
BS according to Rome I criteria over the course of 9 weeks with
 3 month follow-up [61]. Patients were randomized to receive
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ither a CBT intervention as a group or symptom monitoring
ith weekly telephone contact. Significant improvements were
bserved for the CBT group therapy arm over the course of
he study for the cognitive scale for functional bowel disorders
p = 0.002 vs. control group), on the assertiveness questionnaire
p = 0.035), and the short form 36 health survey physical health
omponent scale (p  = 0.036). This study had a small sample size
nd the control group was offered CBT after completion of the
nitial 9 week treatment, which may have influenced the per-
eption of initial treatment effects at the 3 month follow-up.
onetheless, the results indicate that group-directed CBT may
rovide similar relief and benefits in treating IBS.
Taylor et al. incorporated a range of complementary
ind–body therapies while investigating the benefits of group
BT, educational, and hypnotherapy sessions in 158 participants
ver the course of 4 months [62]. Participants had been diag-
osed with IBS according to Rome II criteria and were divided
nto small groups of 4–7 patients who received a combination of
BT, IBS education, and gut-directed hypnotherapy. The pooled
ata for all 23 groups showed marked and significant improve-
ents for psychological and general well-being, gastrointestinal
ymptom rating, and prevention of enjoyment of life scales (all
 < 0.001 post- vs. pre-intervention). Although this study suc-
essfully addressed a holistic approach to IBS treatment, the
onclusions that can be drawn are limited because the effects of
ach therapy are difficult to distinguish.
The current research on the effectiveness of CBT in FBDs
s promising, but due to small sample sizes and heterogeneity
n study protocols, including dosages and duration of interven-
ion, further research with larger sample sizes and standardized
tudy protocols are warranted to establish CBT as an effective
reatment for patients with FBDs.
iofeedback
Biofeedback training, which allows patients to gain control
ver certain physiological functions, also assists them in rec-
gnizing the often subconscious dysfunction through a simple
hysiological measurement (e.g. temperature, blood pressure,
ntestinal distension) and visualization. Biofeedback can then
mploy both motor skill and sensory discrimination training to
mprove the patient’s awareness and allow for adaptations [63].
he use of biofeedback has long been employed in a number of
onditions including substance abuse, hypertension, headaches,
hronic pain, constipation, and anxiety disorders [64]. With
espect to general, functional gastrointestinal disorders, train-
ng specific muscle groups and recognition of symptoms can
ubstantially aid patients, but the voluntary control of smooth
uscles and secretory responses remains very limited [63].
Biofeedback has been evaluated in a number of functional
astrointestinal disorders such as fecal incontinence, functional
norectal pain, irritable bowel syndrome, and functional dys-
epsia. One study, which included 19 patients with functional
isorders, provided participants with an 8-week treatment pro-
ocol of biofeedback training and compared them to a control
roup of 40 patients who received conventional therapy [65].
f the 59 patients, 24 had been diagnosed with IBS while the
t
s
l
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thers had been diagnosed with fibromyalgia, functional cardiac
ain, myofacial pain, or panic and anxiety disorders with som-
tization. The study mainly focused on the feasibility and cost
f the biofeedback treatment rather than evaluation of symp-
om reductions, which were noted as significant (p < 0.05) for
ll conditions in the 11 symptom questionnaire. Results of this
tudy, however, did not indicate any specific variables and fac-
ors that would benefit IBS patients. Also, the overall evaluation
as brief and not well explained, thus limiting replication of the
tudy as well as applicability to other FBDs.
Another study evaluated the effect of biofeedback train-
ng in 21 patients with functional constipation [66]. Patients
ere evaluated before treatment and again after 10 biofeedback
essions as well as home training. Patients reported signif-
cant improvements in several clinical parameters, such as
pontaneous frequency of bowel movement (p < 0.01 post- vs.
re-intervention), straining effort (p  < 0.01), sensation of incom-
lete evacuation (p  < 0.01), stool consistency (p  < 0.01), and
loating (p  < 0.01). In addition, both anxiety and depression
cores also improved significantly (p  < 0.01) following biofeed-
ack intervention. Changes in quality of life showed significance
or some factors but not others, especially physical and social
ole functioning, and mental health. The authors did not find
n indication for an influence of biofeedback on autonomous
ervous system function, which may be attributed to the small
ample size in the study.
Biofeedback has also been evaluated for symptom relief
n patients with IBS with limited results. Small studies using
 variety of physiological measures including bowel sounds,
alloon probes, or general electromyogram and temperature
easures as indicators for stress responses had varied, unpromis-
ng results. There are some indications that certain general
ognitive approaches supported by biofeedback may improve
ymptoms of bloating and GI distress in IBS patients, but more
esearch is needed to substantiate this report. Table 1 includes a
ummary of the clinical studies involving mind–body therapies
or the treatment of functional bowel disorders.
The currently available research for biofeedback is limited
y small sample sizes, mostly uncontrolled study protocols, and
eterogeneity in the use of various biofeedback approaches. Fur-
her research with rigorous trial designs are needed to provide
 higher level of evidence for the benefits of biofeedback in the
reatment of FBDs.
onclusions
Functional bowel disorders remain a challenge for both the
ealthcare providers and patients in diagnosis and treatment.
any pharmacological approaches are unspecific to the dis-
ase and often result in suboptimal outcomes that leave patients
nsatisfied with treatment. The use of mind–body therapies for
he alleviation of symptoms has been evolving with a growing
umber of trials establishing a body of evidence of their effec-
iveness. However, many studies remain challenged by small
ample sizes, incomplete explanation of the study protocol, or
ack of rigor of the study designs that do not utilize control groups
r include baseline characteristics. At present, the strongest
rnal o
s
m
a
o
a
s
t
p
m
m
s
p
t
c
p
i
v
v
d
h
w
b
o
t
c
a
I
b
c
i
r
m
t
n
t
a
[
a
a
p
i
i
i
B
h
a
a
O
C
h
h
p
t
t
t
c
m
r
a
s
t
d
a
p
b
i
o
o
s
F
s
C
A
w
RO. Grundmann, S.L. Yoon / European Jou
cientific support exists for the use of hypnotherapy in the treat-
ent of IBS and potentially other FBDs associated with pain
nd gastrointestinal discomfort. Although research findings for
ther mind–body therapies are limited and not conclusive, these
lternative treatment approaches are not associated with any
ignificant side effects, unlike many available pharmacological
reatments. Thus, whenever a patient has an FBD and standard
harmacological care alone proves to be unsatisfactory then
ind–body therapies should be considered as a viable comple-
ent to standard pharmacological therapies. When comparing
tudies using hypnotherapy, CBT, and brief psychodynamic
sychotherapy, Blanchard reached the conclusion that these
reatments are effective in reducing IBS symptoms without indi-
ating superiority for one treatment over another [67]. He also
oints out that a lack of uniform success in reasonable sized trials
ndicates that further research on a larger scale and comparing
arious mind–body treatment options is necessary to establish
alidity.
In line with the rise in popularity of CAM, the United King-
om National Institute for Health and Clinical Excellence (NHS)
as released guidelines on the diagnosis and treatment of IBS in
hich cognitive behavioral therapy, hypnotherapy, and biofeed-
ack are addressed [68]. While the NHS guidelines suggest an
verall improvement of symptoms and symptom management,
he guidelines highlight the need for larger and well-designed
linical studies. One of the findings was that cognitive behavioral
nd hypnotherapy were generally more effective in refractory
BS patients. However, the NHS guidelines are not clear about
iofeedback and relaxation techniques, largely due to insuffi-
ient research data regarding their effectiveness.
Of importance to the use of mind–body therapies to the med-
cal community is their cost-to-benefit or cost-to-effectiveness
atio which may help to establish such complementary treat-
ent approaches further. In this area, even less data is available
o date. Van Tilburg and colleagues evaluated the cost effective-
ess of mind–body therapies in the treatment of FBDs and found
hat there is a significant cost-benefit to using mind–body ther-
pies and other CAM as complements to conventional therapy
18]. The authors also concluded that most patients are gener-
lly satisfied with conventional care, and are only seeking out
dditional treatment options. Thus, future studies should com-
are the cost-benefit ratio and effectiveness of CAM therapies
n the treatment of FBDs, thus allowing patients to make a more
nformed decision.
Another factor that may limit the use of mind–body therapies
n the treatment of FBDs is access to well-qualified therapists.
oth funding limitations (e.g. CAM therapy not covered by
ealth insurance, unaffordable for low-income households) and
 lack of regulation and adequate training of therapists may limit
ccess and use of mind–body therapies in many populations.
verall though, there has been a steady increase in the use of
AM therapies especially among rural populations that often
ave restricted access to standard treatment providers or do not
ave healthcare coverage to provide for expensive medicine and
hysician costs [69].
Overall, although it is inconclusive to determine the effec-
iveness and usefulness of using mind–body therapies for FBDs,f Integrative Medicine 5 (2013) 296–307 305
he majority of published studies indicate positive outcomes of
hese therapies [14]. Patients who have not responded well to
onventional therapies are best suited to benefit from the use of
ind–body therapies, but CAM treatment can provide additional
elief to patients treated with conventional medicines.
Thus, recommendations for future research related to this
rea include, but are not limited to: (1) study with larger sample
izes and rigorous trial design, (2) examining the mechanisms of
hese interventions to alleviate symptoms, (3) investigating the
osages and durations of the intervention for short-term effects
nd retaining long-term effects, and (4) standardizing the study
rotocols based on a type of mind–body therapy, which would
e beneficial for replication of a study and generalizing the find-
ngs. Finally, a combination of certain mind–body therapies with
ther types of complementary therapies may be beneficial as part
f an integrative and holistic approach to manage the diverse
ymptoms of FBDs.
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